Xeris Pharmaceuticals Shares Rise Following Q3 Earnings Beat and Revenue Growth Forecast
Xeris Pharmaceuticals (XERS) saw its stock price approach a new 52-week high following the release of third-quarter financial results that exceeded analyst expectations. The Chicago-based company reported quarterly revenue of $107.2 million, driving positive momentum in the market. In addition to the earnings beat, management raised its long-term financial outlook, projecting total revenue to surpass $1 billion by the end of the decade. This optimistic guidance reflects confidence in the company's growth trajectory and commercial execution.
